Figure 1.

Oral administration of PSK plus docetaxel induces tumor regression. C57BL/6 mice with established tumors (50 mg) were treated with oral saline control daily, oral PSK (300 mg/kg) daily, i.p. injection of docetaxel (2x weekly) or a combination of PSK and docetaxel for a period of 10–12 days. Mean tumor weight ± standard error measurement (mean ± SEM) are shown for each treatment group of mice (n=7/group). PSK combined with docetaxel significantly suppressed tumor growth as compared to saline control, PSK or docetaxel treatments alone (P<0.05).